Thrombophilia Market Report 2026

Thrombophilia Market Overview

• Thrombophilia market size has reached to $18.18 billion in 2025 • Expected to grow to $26.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.8% • Growth Driver: Surge In Thrombophilic Conditions Fuels Growth In The Thrombophilia Market • Market Trend: Groundbreaking Technological Advances And Long-Acting Drugs On The Horizon • North America was the largest region in 2025.

What Is Covered Under Thrombophilia Market?

Thrombophilia is a blood disorder that increases the risk of blood clotting in the veins and arteries. It can be caused by blood clotting in arteries and veins or by an inherited (genetic) or acquired disposition. It has the potential to cause a heart attack, stroke, kidney failure, and pulmonary embolism. The main types of thrombophilia are factor V leiden, prothrombin 20210, antiphospholipid syndrome, and others. Factor V Leiden is a mutation in one of the blood-clotting factors. The drugs include Heparin, Warfarin, and others with a variety of administration routes, such as oral and parenteral. The end-users include hospitals, home health agencies, specialty centers, and others.

What Is The Thrombophilia Market Growth Forecast?

The thrombophilia market size is expected to see strong growth in the next few years. It will grow to $26.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to expansion of genetic testing services, adoption of AI-based diagnostic tools, integration of telehealth platforms, growth in homecare anticoagulant management, increasing healthcare expenditure in emerging markets. Major trends in the forecast period include personalized anticoagulant therapy, increased genetic screening for thrombophilia, advanced diagnostic testing for blood clotting disorders, rise in awareness programs for blood disorders, integration of telemedicine in thrombophilia management.

Global Thrombophilia Market Segmentation

1) By Type: Factor V Leiden, Prothrombin 20210, Antiphospholipid Syndrome, Other Type 2) By Drugs: Heparin, Warfarin, Other Drugs 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration 4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users Subsegments: 1) By Factor V Leiden: Genetic Testing, Anticoagulant Therapy 2) By Prothrombin 20210: Genetic Testing, Anticoagulant Therapy 3) By Antiphospholipid Syndrome: Antiphospholipid Antibody Testing, Anticoagulant Therapy 4) By Other Types: Protein C Deficiency, Protein S Deficiency, Antithrombin III Deficiency

What Is The Driver Of The Thrombophilia Market?

The increasing prevalence of thrombophilic conditions is expected to propel the growth of the thrombophilia market in the coming years. Thrombophilic diseases, often known as thrombophilia, are a category of illnesses marked by an increased proclivity to develop blood clots (thrombosis). Thrombophilic conditions play an important role in the thrombophilia market, impacting diagnosis, treatment techniques, and current research. For instance, in July 2025, according to PubMed, a US-based publicly accessible online database of biomedical literature, reported that factor V Leiden and prothrombin G202110A mutations significantly raise the prevalence of stillbirth with a pooled OR of 2.35 (95% CI 1.74-3.17) and 2.62 (95% CI 1.79-3.84), respectively. This positive correlation did not change in the sensitivity analysis. Positive correlation was also found between antithrombin deficiency. Therefore, the increasing prevalence of thrombophilic conditions is driving the thrombophilia industry.

Key Players In The Global Thrombophilia Market

Major companies operating in the thrombophilia market are Pfizer Inc., F. Hoffmann-La Roche Limited, Fresenius Kabi AG, Hikma Pharmaceuticals PLC., Novartis AG, Shenzhen Hepalink Pharmaceutical Group Co. Limited, Teva Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim GmbH, Instrumentation Laboratory SpA, Johnson & Johnson, Bristol-Myers Squibb, Roche, Abbott, C. H. Boehringer Sohn, Portola Pharmaceuticals, Daiichi Sankyo, Bayer Group, CSL Behring, Merck & Co Inc., Janssen Pharmaceuticals

Global Thrombophilia Market Trends and Insights

Major companies operating in the thrombophilia market are focusing on developing innovative technologies, such as long-acting fusion protein therapies for coagulation factor replacement, to meet the rising demand for improved treatment durability, fewer administrations, and enhanced patient compliance in bleeding disorders and thrombophilia-related conditions. Long-acting fusion protein therapies combine coagulation factors with carrier proteins or Fc fragments to extend half-life in the bloodstream, reduce dosing frequency compared to traditional factor replacements, and improve overall patient quality of life. For instance, in May 2023, researchers at the University of California, San Diego, developed a groundbreaking technology known as Eloctate that holds the potential to transform the treatment of hemophilia. This innovative approach utilizes a novel fusion protein that significantly enhances the stability and half-life of coagulation factors in the bloodstream. By combining this technology with existing therapies, the researchers aim to create long-acting drugs that require less frequent administration, thereby improving patient compliance and quality of life.

What Are Latest Mergers And Acquisitions In The Thrombophilia Market?

In March 2025, Tempus AI, a US-based provider of artificial intelligence-driven precision medicine, oncology diagnostics, and data analytics platforms, acquired Ambry Genetics for an undisclosed amount. With this acquisition, Tempus AI aimed to expand its hereditary and rare disease testing capabilities, enhance its genetic diagnostics portfolio, and integrate Ambry’s expertise into its AI-driven precision medicine platform. Ambry Genetics is a US-based provider of hereditary and genetic testing services, including diagnostics for inherited conditions such as thrombophilia, cardiology, neurology, and rare diseases.

Regional Insights

North America was the largest region in the thrombophilia market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Thrombophilia Market?

The thrombophilia market consists of sales of rivaroxaban, apixaban, and thrombolytics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Thrombophilia Market Report 2026?

The thrombophilia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the thrombophilia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.